🔗 Share this article

Former Prime Minister Rishi Sunak has intensified his call for a focused screening programme for prostate cancer.

In a recently conducted conversation, he declared being "certain of the immediate need" of establishing such a programme that would be cost-effective, deliverable and "protect countless lives".

His comments come as the British Screening Authority reviews its determination from five years ago against recommending standard examination.

News sources suggest the committee may continue with its present viewpoint.

Athlete Contributes Support to Movement

Gold medal cyclist Chris Hoy, who has late-stage prostate cancer, advocates for younger men to be tested.

He recommends reducing the minimum age for obtaining a prostate-specific antigen blood screening.

At present, it is not routinely offered to asymptomatic males who are below fifty.

The PSA examination is controversial nevertheless. Readings can rise for causes besides cancer, such as infections, resulting in false positives.

Opponents maintain this can result in unnecessary treatment and adverse effects.

Targeted Screening Initiative

The suggested screening programme would concentrate on males between 45 and 69 with a family history of prostate cancer and men of African descent, who experience twice the likelihood.

This population comprises around 1.3 million individuals men in the UK.

Charity estimates propose the programme would require twenty-five million pounds a year - or about eighteen pounds per participant - comparable to bowel and breast cancer screening.

The estimate involves 20% of suitable candidates would be invited yearly, with a seventy-two percent response rate.

Clinical procedures (scans and biopsies) would need to rise by twenty-three percent, with only a moderate increase in healthcare personnel, according to the report.

Clinical Community Reaction

Some medical experts remain sceptical about the benefit of screening.

They argue there is still a possibility that patients will be medically managed for the disease when it is not absolutely required and will then have to live with side effects such as incontinence and impotence.

One respected urology professional commented that "The issue is we can often find abnormalities that doesn't need to be addressed and we risk inflicting harm...and my apprehension at the moment is that harm to benefit ratio isn't quite right."

Individual Experiences

Patient voices are also affecting the discussion.

A particular case concerns a sixty-six year old who, after requesting a prostate screening, was detected with the disease at the time of fifty-nine and was advised it had spread to his pelvis.

He has since received chemical therapy, radiotherapy and endocrine treatment but is not curable.

The patient endorses examination for those who are genetically predisposed.

"This is essential to me because of my children – they are in their late thirties and early forties – I want them checked as soon as possible. If I had been tested at fifty I am confident I might not be in the circumstances I am now," he commented.

Next Actions

The Screening Advisory Body will have to evaluate the information and arguments.

While the latest analysis says the consequences for personnel and availability of a examination system would be feasible, some critics have contended that it would redirect scanning capacity from patients being cared for for different health issues.

The continuing debate underscores the complicated balance between early detection and likely unnecessary management in prostate gland cancer management.